2Q21 earnings presentation

Cash flow and balance sheet highlights Cash and cash equivalents $1,366 million 1H21 cash flows from operations $542 million 1H21 free cash flow¹ $320 million Payment of $355 million for US commercialization rights of Simbrinza Dividend payment of $54 million Capex $222 million Investing in new contact lens manufacturing lines Expect higher capex in 2H21 due to timing of installations Debt $4,122 million No financial covenants Alcon 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. 18

View entire presentation